Table 4.
Comparison of clinical outcomes between teduglutide and placebo in subpopulations
| Clinical outcome | Higher-response subpopulation
|
Lower-response subpopulation
|
||||
|---|---|---|---|---|---|---|
| Teduglutide (n=24) |
Placebo (n=27) |
P-value | Teduglutide (n=19) |
Placebo (n=16) |
P-value | |
| Response rate, n (%) | 21 (87.5) | 7 (25.9) | <0.01* | 6 (31.6) | 6 (37.5) | 0.71 |
| Reduction in PS days, mean (SD) | 1.0 (1.2) | 0.4 (0.9) | 0.01* | 0.8 (1.0) | 0.7 (0.9) | 0.51 |
| Change in SBS-QoL, mean (SD) | −12.2 (31.3) | −8.5 (31.1) | 0.57 | −11.2 (20.5) | −2.6 (30.2) | 0.59 |
Note:
*
P<0.05.
Abbreviations: PS, parenteral support; QoL, quality of life; SBS, short bowel syndrome.